19-year-old hit while crossing street in critical condition

first_img WhatsApp Pinterest Pinterest Twitter 2021 SCHOOL HONORS: Permian High School By admin – May 7, 2018 Facebook Twitter OC employee of the year always learning Facebook An Odessa man is in critical condition after police say he was hit by a vehicle while walking across the street Sunday night in east Odessa.Caleb Sowards, 19, of Odessa was walking north across the 4600 block of Oakwood Drive when a black 2015 GMS Sierra hit him, an Odessa Police Department news release stated. Sowards was not at a crosswalk.OPD and Odessa Fire Rescue responded to a call about a major crash at about 9:49 p.m. Sunday at Oakwood Drive and JBS Parkway.The release stated 27-year-olds Kendal McClendon and Shelbee Davis, both of Odessa, were in the truck traveling east in the 4600 block of Oakwood Drive when the crash occurred. McClendon was driving and Davis was the front passenger.Sowards was transported to Medical Center Hospital with serious bodily injury. There were no reports of any other injuries. The investigation continues, the release stated. ECISD undergoing ‘equity audit’ WhatsApp Local News 19-year-old hit while crossing street in critical condition Home Local News 19-year-old hit while crossing street in critical condition Previous articleFive things you need to know today, May 7Next articleDAILY OIL PRICE: May 7 admin RELATED ARTICLESMORE FROM AUTHOR Hawaiian Roll Ham SlidersSlap Your Mama It’s So Delicious Southern Squash CasseroleUpside Down Blueberry Pie CheesecakePowered By 10 Sec Mama’s Deviled Eggs NextStay last_img read more

Read More »

Global AXL Kinase inhibitor Pipeline Insights 2021: Emerging Drugs Include Sitravatinib (Mirati Therapeutics) and…

first_img Twitter TAGS  Facebook By Digital AIM Web Support – February 19, 2021 Pinterest DUBLIN–(BUSINESS WIRE)–Feb 19, 2021– The “AXL Kinase inhibitor – Pipeline Insight, 2021” drug pipelines has been added to ResearchAndMarkets.com’s offering. This “AXL Kinase inhibitor – Pipeline Insight, 2021,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in AXL Kinase inhibitor pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space. Report HighlightsThe companies and academics are working to assess challenges and seek opportunities that could influence AXL Kinase inhibitor R&D. The therapies under development are focused on novel approaches for AXL Kinase inhibitor. AXL Kinase inhibitor Emerging Drugs Chapters This segment of the AXL Kinase inhibitor report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases. AXL Kinase inhibitor Emerging DrugsBemcentinib: BerGenBio / Rigel Pharmaceuticals Bemcentinib (BGB324) is a potent, selective and orally bioavailable AXL inhibitor and a potential future cornerstone to therapy for aggressive diseases, including immune-evasive, therapy resistant cancers, fibrosis and viral infection. The drug is in phase II program, focused on establishing proof of concept that bemcentinib may reverse and prevent resistance to immune, targeted and chemotherapy.Sitravatinib: Mirati Therapeutics Sitravatinib is an oral, potent, spectrum-selective RTK inhibitor. It inhibits several closely related RTKs, including the TAM family (TYRO3, AXL and MER), VEGFR2 and KIT. This inhibition weakens the cancer’s defenses in the tumor microenvironment. AXL Kinase inhibitor: Therapeutic Assessment This segment of the report provides insights about the different AXL Kinase inhibitor drugs segregated based on following parameters that define the scope of the report, such as: Major Players working on AXL Kinase inhibitor There are approx. 15+ key companies which are developing the AXL Kinase inhibitor. The companies which have their AXL Kinase inhibitor drug candidates in the most advanced stage, i.e. Phase III include, Mirati Therapeutics. The report covers around 15+ products under different phases of clinical development likeLate-stage products (Phase III)Mid-stage products (Phase II)Early-stage products (Phase I/II and Phase I)Pre-clinical and Discovery stage candidatesDiscontinued & Inactive candidatesRoute of Administration AXL Kinase inhibitor pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such asInfusionIntradermalIntramuscularIntranasalIntravaginalOralParenteralSubcutaneousTopicalMolecule Type Products have been categorized under various Molecule types such asVaccinesMonoclonal AntibodyPeptidesPolymerSmall moleculeProduct Type The drugs have been categorized under various product types like Mono, Combination and Mono/Combination. AXL Kinase inhibitor: Pipeline Development Activities The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses AXL Kinase inhibitor therapeutic drugs key players involved in developing key drugs. Pipeline Development Activities The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging AXL Kinase inhibitor drugs. AXL Kinase inhibitor Report Insights Global AXL Kinase inhibitor Pipeline Insights 2021: Emerging Drugs Include Sitravatinib (Mirati Therapeutics) and Bemcentinib (BerGenBio / Rigel Pharmaceuticals) – ResearchAndMarkets.com Twitter AXL Kinase inhibitor Pipeline AnalysisTherapeutic AssessmentUnmet NeedsImpact of Drugs AXL Kinase inhibitor Report AssessmentPipeline Product ProfilesTherapeutic AssessmentPipeline AssessmentInactive drugs assessmentUnmet Needs Key Questions Answered Current Scenario and Emerging Therapies:How many companies are developing AXL Kinase inhibitor drugs?How many AXL Kinase inhibitor drugs are developed by each company?How many emerging drugs are in mid-stage, and late-stage of development for AXL Kinase inhibitor?What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the AXL Kinase inhibitor therapeutics?What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?What are the clinical studies going on for AXL Kinase inhibitor and their status?What are the key designations that have been granted to the emerging drugs? Key PlayersBerGenBioRigel PharmaceuticalsMirati TherapeuticsIpsenSignalChem LifesciencesArcus BiosciencesSymphogenQurient CoDaiichi Sankyo CompanyAraviveExelixis Key ProductsBemcentinibSitravatinibCabozantinibResearch programme: TAM inhibitorsResearch programme: AXL receptor tyrosine kinase inhibitorsSym 028Q-702AB 329Aravive S6XL092 For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/ti83ou View source version on businesswire.com:https://www.businesswire.com/news/home/20210219005221/en/ CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 KEYWORD: INDUSTRY KEYWORD: HEALTH GENERAL HEALTH SOURCE: Research and Markets Copyright Business Wire 2021. PUB: 02/19/2021 05:50 AM/DISC: 02/19/2021 05:50 AM http://www.businesswire.com/news/home/20210219005221/en WhatsApp WhatsApp Pinterest Facebook Local NewsBusiness Previous articleEverbridge annuncia di essersi aggiudicata cinque contratti relativi alle soluzioni Public Warning con società di trasmissioni wireless, governi e Stati finalizzati alla protezione delle persone e delle aziende in Europa e in AsiaNext articleWilliams career-high 32 sparks WSU to romp over Cal 82-51 Digital AIM Web Supportlast_img read more

Read More »